Co-Authors
This is a "connection" page, showing publications co-authored by Efstathios Kastritis and Meletios Dimopoulos.
Connection Strength
22.486
-
Antibody Response After Initial Vaccination for SARS-CoV-2 in Patients With Amyloidosis. Hemasphere. 2021 Aug; 5(8):e614.
Score: 0.956
-
Significant reduction in the visits to the emergency room department during the COVID-19 pandemic in a tertiary hospital in Greece: Indirect victims of the pandemic? Medicine (Baltimore). 2020 Dec 24; 99(52):e23845.
Score: 0.920
-
Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic. Br J Haematol. 2020 08; 190(3):346-357.
Score: 0.891
-
A revised international prognostic score system for Waldenström's macroglobulinemia. Leukemia. 2019 11; 33(11):2654-2661.
Score: 0.824
-
A 50-Year-Long Study of Waldenström Macroglobulinemia. Mayo Clin Proc. 2019 03; 94(3):394-396.
Score: 0.811
-
Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis. Amyloid. 2018 Dec; 25(4):234-241.
Score: 0.805
-
Thalidomide for myeloma: still here? Lancet Haematol. 2018 10; 5(10):e439-e440.
Score: 0.788
-
Proteasome Inhibitors in Waldenström Macroglobulinemia. Hematol Oncol Clin North Am. 2018 Oct; 32(5):829-840.
Score: 0.778
-
Managing myeloma with limited resources in the era of novel drugs. Leuk Lymphoma. 2018 10; 59(10):2269-2270.
Score: 0.775
-
Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis. Blood Cancer J. 2018 05 24; 8(5):46.
Score: 0.769
-
Denosumab for myeloma bone disease: ready for prime time? Lancet Oncol. 2018 03; 19(3):277-278.
Score: 0.754
-
Disease control should be the goal of therapy for WM patients. Blood Adv. 2017 Nov 28; 1(25):2483-2485.
Score: 0.744
-
Daratumumab combinations: what can we learn? Blood. 2017 08 24; 130(8):957-958.
Score: 0.730
-
Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy. Leuk Lymphoma. 2017 Oct; 58(10):2304-2309.
Score: 0.720
-
Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy. Am J Hematol. 2017 Jul; 92(7):632-639.
Score: 0.718
-
Prognosis and risk assessment in AL amyloidosis - There and back again. Br J Haematol. 2017 05; 177(3):343-345.
Score: 0.715
-
Cardiac and renal complications of carfilzomib in patients with multiple myeloma. Blood Adv. 2017 Feb 28; 1(7):449-454.
Score: 0.706
-
Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies. Am J Hematol. 2015 Apr; 90(4):E60-5.
Score: 0.616
-
When a little aspirin may be enough. Blood. 2012 Jan 26; 119(4):905-6.
Score: 0.496
-
Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients. BMC Med. 2021 08 23; 19(1):208.
Score: 0.241
-
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. Blood Cancer J. 2021 08 02; 11(8):138.
Score: 0.240
-
Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers. Cells. 2021 07 30; 10(8).
Score: 0.240
-
Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine. Clin Exp Med. 2021 Jul 20.
Score: 0.239
-
Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose. Blood. 2021 07 01; 137(26):3674-3676.
Score: 0.238
-
High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events. Vaccines (Basel). 2021 Jul 01; 9(7).
Score: 0.238
-
Continuing Cancer Therapy through the Pandemic While Protecting Our Patients: Results of the Implementation of Preventive Strategies in a Referral Oncology Unit. Cancers (Basel). 2021 Feb 12; 13(4).
Score: 0.232
-
Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. J Biomed Sci. 2021 Jan 12; 28(1):9.
Score: 0.231
-
Emerging treatment strategies for COVID-19 infection. Clin Exp Med. 2021 May; 21(2):167-179.
Score: 0.228
-
Response of an oncology unit in the midst of the COVID-19 outbreak. J Oncol Pharm Pract. 2020 Dec; 26(8):1947-1952.
Score: 0.227
-
Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report. Life (Basel). 2020 Sep 21; 10(9).
Score: 0.226
-
Organ-specific manifestations of COVID-19 infection. Clin Exp Med. 2020 Nov; 20(4):493-506.
Score: 0.224
-
Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes. Rheumatol Int. 2020 09; 40(9):1353-1360.
Score: 0.223
-
Hematological findings and complications of COVID-19. Am J Hematol. 2020 07; 95(7):834-847.
Score: 0.221
-
Reactive Vasodilation Predicts Mortality in Primary Systemic Light-Chain Amyloidosis. Circ Res. 2019 09 27; 125(8):744-758.
Score: 0.209
-
Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome. Ann Hematol. 2019 Jun; 98(6):1427-1434.
Score: 0.203
-
Hereditary systemic amyloidosis caused by K19T apolipoprotein C-II variant. Amyloid. 2019 Mar; 26(1):52-53.
Score: 0.202
-
Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma. Int J Cancer. 2019 07 15; 145(2):559-568.
Score: 0.201
-
Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients. Leuk Lymphoma. 2019 03; 60(3):619-628.
Score: 0.201
-
Evaluation of pre-mir-34a rs72631823 single nucleotide polymorphism in triple negative breast cancer: A case-control study. Oncotarget. 2018 Dec 11; 9(97):36906-36913.
Score: 0.200
-
How I treat rituximab refractory patients with WM. Oncotarget. 2018 Dec 07; 9(96):36824-36825.
Score: 0.200
-
Prognostic factors for multiple myeloma in the era of novel therapies. Expert Rev Hematol. 2018 11; 11(11):863-879.
Score: 0.198
-
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia. N Engl J Med. 2018 Jun 21; 378(25):2399-2410.
Score: 0.193
-
How We Manage Patients with Plasmacytomas. Curr Hematol Malig Rep. 2018 06; 13(3):227-235.
Score: 0.193
-
Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma. Blood Cancer J. 2018 05 11; 8(5):42.
Score: 0.192
-
Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group. Blood Cancer J. 2018 03 09; 8(3):31.
Score: 0.190
-
Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis. Blood. 2018 04 05; 131(14):1568-1575.
Score: 0.188
-
Rare manifestations of extramedullary myeloma: testicular plasmacytomas. Leuk Lymphoma. 2018 08; 59(8):2002-2004.
Score: 0.186
-
The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents. Blood. 2018 01 25; 131(4):464-467.
Score: 0.186
-
An overview of the role of carfilzomib in the treatment of multiple myeloma. Expert Opin Pharmacother. 2017 Dec; 18(17):1883-1897.
Score: 0.186
-
Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases. Leuk Lymphoma. 2018 04; 59(4):983-987.
Score: 0.182
-
Efficacy and safety of elotuzumab for the treatment of multiple myeloma. Expert Opin Drug Saf. 2017 Feb; 16(2):237-245.
Score: 0.175
-
Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia. Expert Opin Investig Drugs. 2017 Feb; 26(2):197-205.
Score: 0.175
-
Glomerular expression of matrix metalloproteinases in AL-amyloidosis and association with renal function at the time of kidney biopsy. Clin Nephrol. 2016 Jan; 85(1):44-54.
Score: 0.163
-
Patterns of pharmaceuticals use during the first wave of COVID-19 pandemic in Athens, Greece as revealed by wastewater-based epidemiology. Sci Total Environ. 2021 Dec 01; 798:149014.
Score: 0.060
-
Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review. J Infect. 2021 07; 83(1):1-16.
Score: 0.059
-
Recovery of Innate Immune Cells and Persisting Alterations in Adaptive Immunity in the Peripheral Blood of Convalescent Plasma Donors at Eight Months Post SARS-CoV-2 Infection. Microorganisms. 2021 Mar 06; 9(3).
Score: 0.058
-
SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response. Vaccines (Basel). 2021 Mar 02; 9(3).
Score: 0.058
-
Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection. Viruses. 2020 12 25; 13(1).
Score: 0.058
-
Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic. Hemasphere. 2020 Aug; 4(4):e433.
Score: 0.056
-
Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. J Clin Oncol. 2019 06 01; 37(16):1403-1411.
Score: 0.051
-
Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin. Blood. 2019 02 14; 133(7):710-723.
Score: 0.050
-
Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study. Blood Cancer J. 2018 11 07; 8(11):102.
Score: 0.050
-
European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia. 2018 09; 32(9):1883-1898.
Score: 0.049
-
Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review. Lancet Haematol. 2018 Jul; 5(7):e299-e309.
Score: 0.048
-
Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent. Oncotarget. 2018 Apr 03; 9(25):17797-17809.
Score: 0.048
-
Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2018 06; 18(6):431-437.
Score: 0.048
-
Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events. Sci Rep. 2017 12 19; 7(1):17802.
Score: 0.047
-
Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies. Eur J Haematol. 2017 Nov; 99(5):409-414.
Score: 0.046
-
Dynamic contrast-enhanced magnetic resonance imaging parameters correlate with advanced revised-ISS and angiopoietin-1/angiopoietin-2 ratio in patients with multiple myeloma. Ann Hematol. 2017 Oct; 96(10):1707-1714.
Score: 0.045
-
Emerging treatment approaches for myeloma-related bone disease. Expert Rev Hematol. 2017 Mar; 10(3):217-228.
Score: 0.044
-
High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents. Leuk Res. 2010 Mar; 34(3):399-402.
Score: 0.026